Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Santa Monica, California 90403


The purpose of this clinical investigation is to evaluate the safety and effectiveness of the ACD in the single level surgical treatment of patients with symptomatic cervical degenerative disc disease. The primary follow-up information obtained from this clinical investigation are used to support a PMA application for the ACD.


Inclusion Criteria: All patients participating in this study must meet all of the following inclusion criteria: 1. Cervical degenerative disc disease defined as: intractable radiculopathy and/or myelopathy with at least one of the following items producing symptomatic nerve root and/or spinal cord compression which is documented by patient history (e.g., neck and/or arm pain], functional deficit, and/or neurological deficit, and radiographic studies (e.g., CT, MRI, x-rays, etc). 1. herniated disc; 2. osteophyte formation; 2. One cervical level requiring surgical treatment; 3. C3-C4 disc to C6-C7 disc level of involvement; 4. Unresponsive to non-operative treatment for approximately six weeks or has the presence of progressive symptoms or signs of nerve root/spinal cord compression in the face of continued non-operative management; 5. No previous surgical intervention at the involved level or any subsequent, planned/staged surgical procedure at the involved or adjacent level(s); 6. Is at least 18 years of age, inclusive, at the time of surgery; 7. Preoperative Neck Disability Index score > or = 30; 8. Has a preoperative neck pain score of > 20 based on the Preoperative Neck and Arm Pain Questionnaire. 9. If of child-bearing potential, patient is not pregnant at the time of surgery; 10. Is willing to comply with the study plan and sign the Patient Informed Consent Form. Exclusion Criteria: A patient meeting any of the following criteria is to be excluded from the study: 1. Has a cervical spinal condition other than symptomatic cervical disc disease requiring surgical treatment at the involved level; 2. Documented or diagnosed cervical instability defined by dynamic (flexion/extension) radiographs showing: 1. Sagittal plane translation > 3.5 mm or; 2. Sagittal plane angulation > 20. 3. More than one cervical level requiring surgical treatment; 4. Has a fused level adjacent to the level to be treated; 5. Has severe pathology of the facet joints of the involved vertebral bodies; 6. Previous surgical intervention at the involved level; 7. Has been previously diagnosed with osteopenia or osteomalacia; 8. Has any of the following that may be associated with a diagnosis of osteoporosis (if Yes to any of the below risk factors, a DEXA Scan will be required to determine eligibility): 1. Postmenopausal Non-Black female over 60 years of age and weighs less than 140 pounds. 2. Postmenopausal female that has sustained a non-traumatic hip, spine, or wrist fracture. 3. Male over the age of 70. 4. Male over the age of 60 that has sustained a non-traumatic hip or spine fracture. If the level of BMD is a T score of -3.5 or a T score of -2.5 with vertebral crush fracture, then the patient is excluded from the study. 9. Has presence of spinal metastases; 10. Has overt or active bacterial infection, either local or systemic; 11. Has severe insulin dependent diabetes; 12. Has chronic or acute renal failure or prior history of renal disease; 13. Has fever (temperature > 101 F oral) at the time of surgery; 14. Has a documented allergy or intolerance to stainless steel, titanium, or a titanium alloy; 15. Is mentally incompetent. (If questionable, obtain psychiatric consult); 16. Is a prisoner; 17. Is pregnant; 18. Is an alcohol and/or drug abuser as defined by currently undergoing treatment for alcohol and/or drug abuse; 19. Has received drugs which may interfere with bone metabolism within two weeks prior to the planned date of spinal surgery (e.g., steroids or methotrexate), excluding routine perioperative anti-inflammatory drugs; 20. Has a history of an endocrine or metabolic disorder known to affect osteogenesis (e.g., Paget's Disease, renal osteodystrophy, Ehlers-Danlos Syndrome, or osteogenesis imperfecta); 21. Has a condition that requires postoperative medications that interfere with the stability of the implant or fusion, such as steroids. (This does not include low dose aspirin for prophylactic anticoagulation and routine perioperative anti-inflammatory drugs); 22. Has received treatment with an investigational therapy within 28 days prior to implantation surgery or such treatment is planned during the16 weeks following Artificial Cervical Disc implantation.

Study is Available At:

Original ID:




Secondary ID:

Study Acronym:

Brief Title:

PRESTIGE® Cervical Disc Study

Official Title:

Investigation of the PRESTIGE® Cervical Disc Device at a Single Level for Symptomatic Cervical Disc Disease

Overall Status:


Study Phase:




Minimum Age:

18 Years

Maximum Age:


Quick Facts

Healthy Volunteers
Oversight Has DMC
Study Is FDA Regulated
Study Is Section 801
Has Expanded Access

Study Source:

Medtronic Spinal and Biologics

Oversight Authority:

United States: Food and Drug Administration

Reasons Why Stopped:

Study Type:


Study Design:

Allocation: Randomized, Endpoint Classification:

Number of Arms:


Number of Groups:


Total Enrollment:


Enrollment Type:


Study Dates

Start Date:October 2002
Completion Date:May 2013
Completion Type:Actual
Primary Completion Date:July 2006
Primary Completion Type:Actual
Verification Date:February 2013
Last Changed Date:July 31, 2013
First Received Date:March 19, 2008

Study Outcomes

Outcome Type:Primary Outcome
Measure:The primary endpoint is overall success, which consists of NDI score, neuro status success, with/without FSU disc ht success, no serious AE classified as "implant/surgical procedure associated", and no secondary surgical procedure classified as failure
Time Frame:24 months
Safety Issues:True
Outcome Type:Secondary Outcome
Measure:The secondary outcomes are radiographic success, medical outcomes SF-36 patient survey (MCS & PCS) success, neck pain status, arm pain status, patient satisfaction, patient global perceived effect, gait assessment, foraminal compression test
Time Frame:24 months
Safety Issues:False

Study Interventions

Intervention Type:Device
Name:Allograft Fusion and ATLANTIS™ Cervical Plate Syst
Description:The patients that received the control treatment underwent a single level anterior cervical fusion procedure involving allograft bone and the ATLANTIS™ Cervical Plate System.
Arm Name:Control
Other Name:ATLANTIS™
Intervention Type:Device
Name:PRESTIGE® Cervical Disc
Description:The PRESTIGE® Cervical Disc is a stainless steel device that was inserted into the intervertebral disc space. The device is composed of two metal plates that interface via a ball and socket mechanism permitting segmental spinal motion.
Arm Name:Investigational
Other Name:PRESTIGE®

Study Arms

Study Arm Type:Active Comparator
Arm Name:Control
Description:The Control cohort are patients that receive the fusion treatment.
Study Arm Type:Experimental
Arm Name:Investigational
Description:The Investigational cohort are the study patients that received the PRESTIGE® Cervical Disc.

Study Agencies

Agency Class:Industry
Agency Type:Lead Sponsor
Agency Name:Medtronic Spinal and Biologics

Sample and Retention Information

There are no available Sample and Retention Information

Study References

Reference Type:Reference
Citation:Mummaneni PV, Burkus JK, Haid RW, Traynelis VC, Zdeblick TA. Clinical and radiographic analysis of cervical disc arthroplasty compared with allograft fusion: a randomized controlled clinical trial. J Neurosurg Spine. 2007 Mar;6(3):198-209.
Reference Type:Reference
Citation:Burkus JK, Haid RW, Traynelis VC, Mummaneni PV. Long-term clinical and radiographic outcomes of cervical disc replacement with the Prestige disc: results from a prospective randomized controlled clinical trial. J Neurosurg Spine. 2010 Sep;13(3):308-18.

Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

This study is not currently recruiting Study Participants. The form below is not enabled.